Canon Medical AI vs Elucid

Elucid's PlaqueIQ quantifies coronary plaque on CT angiograms. It has FDA 510(k)s from September 2024 (K241524) and September 2026 (K261855), and the K241524 cleared claim covers plaque quantification to support clinicians and stops short of diagnosing disease. Category I CPT 75577 has applied since January 2026, with a national average payment near $1,012 at imaging centers, paid to the performing site and not to Elucid. Elucid bills providers per analysis. The workflow sends CCTA images to Elucid, where trained analysts segment the arteries. Turnaround time is unpublished. Canon's AiCE is deep-learning reconstruction cleared as part of CT and MR scanners, 28 of Canon's 98 openFDA clearances carry AiCE in the device name, and Canon's dose-reduction claim of up to 82.4% comes from a phantom study. A cardiology group sending CCTA out for plaque analysis is Elucid's audience, and a radiology department replacing scanners is Canon's. A scanner-bundled reconstruction engine and a per-analysis plaque service do not replace each other.